D. Papadatos-Pastos

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome

Zacharenia Saridaki, D. Papadatos-Pastos, Maria Tzardi et al. · British Journal of Cancer · 2010 · 118 citations · Full text

Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer

N. Xenidis, V. Markos, Stella Apostolaki et al. · Annals of Oncology · 2007 · 73 citations · Full text

Breast Oncology, Medicine, Immunology +11

A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

Víctor Moreno, Richard D. Baird, Kinjal Shah et al. · Journal of Clinical Oncology · 2011 · 39 citations

Gdc-0941 Plasma Concentrations, Advanced Solid Tumors, Tumor Biology +17

Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.

Brent O’Carrigan, Maria J. de Miguel, D. Papadatos-Pastos et al. · Journal of Clinical Oncology · 2016 · 33 citations

Pathology, Pharmacotherapy, Tumor Biology +17

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem

Dimitrios C. Ziogas, D. Papadatos-Pastos, Kiruthikah Thillai et al. · European Journal of Gastroenterology & Hepatology · 2016 · 19 citations